<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069831</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 21-0781</org_study_id>
    <nct_id>NCT05069831</nct_id>
  </id_info>
  <brief_title>JAK Inhibition in Food Allergy</brief_title>
  <official_title>JAK Inhibition in Food Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the role for an oral targeted medication, abrocitinib, as a new&#xD;
      treatment option for food allergy patients that would avoid injections. Abrocitinib, which&#xD;
      has successfully completed phase three trials for atopic dermatitis, could serve as a single&#xD;
      therapy for two conditions in many patients with multiple atopic conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a single center, blinded, randomized pilot study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in basophil activation</measure>
    <time_frame>baseline and after 4 months of treatment</time_frame>
    <description>change in basophil activation as measured by %CD63 AUC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in skin prick test</measure>
    <time_frame>baseline and after 4 months of treatment</time_frame>
    <description>change in skin prick test size after four months of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in antigen-specific T-cell</measure>
    <time_frame>baseline and after 4 months of treatment</time_frame>
    <description>change in antigen-specific T-cell response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in specific immunoglobulin E (sIgE)</measure>
    <time_frame>baseline and after 4 months of treatment</time_frame>
    <description>change in sIgE to allergic trigger food(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in FENO</measure>
    <time_frame>baseline and after 4 months of treatment</time_frame>
    <description>Fractional Exhaled Nitric Oxide (FeNO) level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Food Allergy</condition>
  <arm_group>
    <arm_group_label>Abrocitinib 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive 100mg of the study drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abrocitinib 200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive 200mg of the study drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abrocitinib</intervention_name>
    <description>Abrocitinib daily for 4 months</description>
    <arm_group_label>Abrocitinib 100mg</arm_group_label>
    <arm_group_label>Abrocitinib 200mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 - 50 years old&#xD;
&#xD;
          -  Participant must be able to understand and perform informed consent.&#xD;
&#xD;
          -  IgE-mediated food allergy to at least one of the following foods as defined by&#xD;
             (regarding at least one of the foods):&#xD;
&#xD;
             Â° Foods: peanut, cashew, walnut, hazelnut, sesame, cod, and/or shrimp, history of an&#xD;
             acute allergic reaction (urticaria, angioedema, cough, wheeze, and/or repetitive&#xD;
             vomiting within an hour of ingestion, and history of positive skin or serum IgE test,&#xD;
             and current strict avoidance of the food, and current possession of&#xD;
             physician-prescribed self-injectable epinephrine, and skin test wheal 5 mm or greater&#xD;
             average diameter&#xD;
&#xD;
          -  Atopic dermatitis (AD) diagnosis for at least 1 year with at least 7% current BSA&#xD;
             involvement.&#xD;
&#xD;
          -  If female of childbearing potential, must have a negative pregnancy test (serum or&#xD;
             urine) and agree to abstinence or acceptable contraception.&#xD;
&#xD;
          -  Plan to remain in the Tri-State area during the trial for visits.&#xD;
&#xD;
          -  Must agree to avoid prolonged exposure to the sun and not to use tanning booths,&#xD;
             sunlamps, or other ultraviolet (UV) light sources during the study.&#xD;
&#xD;
          -  If receiving concomitant medications for any reason other than AD, must be on a stable&#xD;
             regimen, which is defined as not starting a new drug or changing dosage within 7 days&#xD;
             or 5 half-lives (whichever is longer) prior to Day 1 and through the duration of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling or unable to give written informed consent or comply with protocol.&#xD;
&#xD;
          -  Unable to swallow pill.&#xD;
&#xD;
          -  Use of dupilumab within 6 weeks of enrollment.&#xD;
&#xD;
          -  Prior use or allergy to drugs related to abrocitinib (ruxolitinib, upadacitinib, etc).&#xD;
&#xD;
          -  Use of any other biologic (monoclonal antibody) medication within 12 weeks or 5&#xD;
             half-lives of drug, if known.&#xD;
&#xD;
          -  Allergy to any excipients within abrocitinib.&#xD;
&#xD;
          -  Use of build-up environmental immunotherapy; any food oral immunotherapy;or systemic&#xD;
             oral, IV or IM steroids including but not limited to- prednisone, methylprednisolone,&#xD;
             prednisolone, solumedrol, solucortef, dexamethasone in the past 4 weeks or 5&#xD;
             half-lives of drug, if known.&#xD;
&#xD;
          -  Use of CYP2C9 and CYP2C19 inducers (such as carbamazepine, norfluoxetine, etc.) within&#xD;
             5 half-lives of the inducer plus 14 days prior to the first dose of study&#xD;
             intervention.&#xD;
&#xD;
          -  Use of CYP2C9 and CYP2C19 inhibitors within 1 week of first dose of study intervention&#xD;
             or within 5 half-lives (if known) of the inhibitor, whichever is longer.&#xD;
&#xD;
          -  Unable to stop long-acting antihistamines within minimum wash out period required for&#xD;
             SPTs at screening and site visits&#xD;
&#xD;
          -  History of or significant risk factor(s) for cardiovascular disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Sicherer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emma Guttman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yair Bitton, MBA, MPH</last_name>
    <phone>347-466-2547</phone>
    <email>yair.bitton@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Scott Sicherer, MD</last_name>
    <email>scott.sicherer@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Yair Bitton, MBA, MPH</last_name>
      <email>yair.bitton@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Scott Sicherer</last_name>
      <email>scott.sicherer@mssm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Scott Sicherer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>September 25, 2021</last_update_submitted>
  <last_update_submitted_qc>September 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Scott Sicherer</investigator_full_name>
    <investigator_title>Professor, Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Food Allergy</keyword>
  <keyword>JAK</keyword>
  <keyword>JAK Inhibitor</keyword>
  <keyword>Abrocitinib</keyword>
  <keyword>Immunoglobulin E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abrocitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>data will be provided as a manuscript</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

